Tips to supporting our brothers and sisters with cancerFirefighter Cancer Support Network

In this interview, Laura Zitella will be discussing challenges and considerations for management and prevention of infection in the oncology setting—in both patients with solid tumors and those with hematologic malignancies.Cancer Network

This interview covers standards for healthcare provider competency in offering comprehensive genetic services, and highlighting genetics/genomics resources for nurses.Cancer Network

In this interview, Tami Borneman, who is presenting a poster at the 38th Annual ONS Congress, will discuss spirituality: what it means, and how spiritual interventions can benefit patients with cancer.Cancer Network

This interview covers symptom management and quality-of-life outcomes in cancer clinical trials, which are being incorporated more readily as secondary and sometimes primary trial endpoints.Cancer Network

In this interview, ahead of the AACR annual meeting, we speak with Dr. Julie Brahmer, of Johns Hopkins School of Medicine, who is giving a presentation on immunotherapy in lung cancer, and is one of the clinical investigators of the extensive phase I trial of the anti–PD-1 antibody nivolumab.Cancer Network

This interview covers symptom management and quality-of-life outcomes in cancer clinical trials, which are being incorporated more readily as secondary and sometimes primary trial endpoints.Cancer Network

As part of our coverage for the 30th Annual Miami Breast Cancer Conference, we bring you an interview with Dr. Mark Pegram, director of the breast cancer program at the Stanford Women’s Cancer Center and codirector of the molecular therapeutics program. Dr. Pegram will be discussing the potential for novel HER2 combination therapies at the conferen…

In this interview we discuss the dissemination of research results, clinical trials, and other oncology news using social media, as well as what type of media oncologists use, and how useful and relevant this type of information is for most oncologists.Cancer Network

In this interview we discuss HPV-associated cancers, which are on the rise, and the low vaccination coverage for HPV with Edgar Simard, PhD, MPH, senior epidemiologist of surveillance research, who studies the impact of prevention and screening on cancer incidence at the American Cancer Society.Cancer Network

Ahead of the ASCO GU meeting, we spoke with two symposium committee members, Dr. Mack Roach, of the University of California, San Francisco, and Dr. Hans T. Chung, of the University of Toronto, about early treatment and surveillance of prostate cancer patients.Cancer Network

In this interview we discuss the current management and latest treatments and agents in development for multiple myeloma with Dr. Kenneth Anderson of the Dana-Farber Cancer Institute.Cancer Network

In this interview we discuss the latest treatments and research for gastrointestinal cancers with Dr. Cathy Eng, associate professor, department of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center.Cancer Network

In this interview we discuss the latest chronic myeloid leukemia treatment and research with Dr. Michael Deininger, chief of the division of hematology at the University of Utah School of Medicine.Cancer Network

In this interview we discuss what patients expect from their cancer treatment with Deborah Schrag, MD, MPH, associate professor at Harvard Medical School. Dr. Schrag recently published a study that aimed to discover how patients with advanced cancer understand the purpose of their chemotherapy treatment.…

Today we speak with Steven T. Rosen, MD, about a couple of the projects he and his group are working on, repurposing old drugs for the treatment of multiple myeloma, that will be presented this year at ASH.Cancer Network

To kick off SABCS 2012, we discuss the use of molecular testing for the diagnosis and treatment of breast cancer patients in the clinical setting with Dr. Antonio Wolff of the Kimmel Cancer Center at Johns Hopkins University, one of the presenter's during the "Practical Use of Molecular Profiling" session at this year's symposium.…

In this podcast we discuss the recent advances in the management and treatment of metastatic melanoma with Jeffrey Sosman, MD, medical oncologist and director of the Melanoma and Tumor Immunotherapy Program at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.Cancer Network

In this podcast we discuss integrating palliative care into standard oncology care with Thomas J. Smith, director of palliative medicine at Sidney Kimmel Comprehensive Cancer Center.Cancer Network

In this podcast we discuss the long-term effects of chemotherapy on the cognitive function of cancer patients and the current status of research in this field.Cancer Network

We speak with Clifford Hudis, MD, Memorial Sloan-Kettering Cancer Center, about the recent advances in breast cancer treatment and the top news to come out of this year’s ASCO Breast Cancer Symposium.Cancer Network

The cost of cancer treatment has at least doubled since 1987 and there does not appear to be any hint that cancer care costs will decline. In this podcast we discuss the reasons for the increase in costs, as well as the ethics of cancer care cost containment.Cancer Network

Chemotherapy regimens that 10 years ago cost $30,000 have now increased ten-fold. Could a new research facility help make cancer care affordable again? We speak with Dr. Scott Ramsey to find out about this new facility, the Institute for Cancer Outcomes Research and Evaluation, which aims to do just that.…

We speak with Dr. Ian Thompson about hot button issues in prostate cancer today: which patitents should be screened, which should be biopsied, and whether to treat or observe early disease.Cancer Network

We speak with two practicing oncologists, Dr. Paul R. Helft and Dr. David Eagle, about how the recent Supreme Court decision to uphold the Affordable Care Act will affect oncology practices and cancer patients.Cancer Network

We speak with Patricia S. Steeg, PhD, who has recently written a perspective in the journal Nature calling for a shift in both the types of drugs that are developed for breast cancer and in the way clinical trials are designed and executed.Cancer Network

We speak with Dr. Sara Hurvitz, director of the breast cancer program at the University of California in Los Angeles. Dr. Hurvitz is actively involved in translational phase I/II breast cancer clinical trials as well as in research to better define distinct types of breast tumors to better design novel targeted therapies.…

We discuss the diagnosis and treatment of metastatic pancreatic cancer with Dr. Diane Simeone, who is involved in both pancreatic cancer clinical trials as well as research to better characterize important pancreatic cancer pathways and identify biomarkers for the disease.Cancer Network

We present an exclusive interview with Dr. Kimberly Blackwell, Duke Cancer Institute, who discusses some of the most important information to come out of this year’s meeting, including the EMILIA study, and talks about the future of breast cancer research.Cancer Network

We speak with Dr. Hagop Kantarjian of the M.D. Anderson Cancer Center, who shares his impressions of some of the highlights of this year’s ASCO meeting with regard to hematologic malignancies.Cancer Network

We present an exclusive interview with Joel W. Neal, MD, PhD, who discusses some of the most important information to come out of this year’s meeting and talks about the future of lung cancer research.Cancer Network

In this exclusive interview, Michael B. Atkins, MD, director of the Georgetown Lombardi Comprehensive Cancer Center, discusses some of the most important melanoma research to come out of this year’s ASCO meeting and talks about the future of melanoma therapies.Cancer Network

The debate over screening for lung cancer continues. While there have been many advances in treatment for late-stage disease, screening and prevention are likely the most cost effective and best approaches to preventing lung cancer deaths.Cancer Network

In this interview we speak with two prostate cancer experts, Andrew J. Armstrong and Tomasz M. Beer, both of whom are actively involved in the research and clinical trials of novel agents, on the topic of newly available and upcoming treatment options for patients with castration-resistant prostate cancer.…

Ductal carcinoma in situ (DCIS) is the most commonly diagnosed, noninvasive type of breast cancer in women. In this interview, Dr. Lance Liotta and Professor Virginia Espina, whose laboratory has been one the first to successfully culture living DCIS cells, discuss novel ways to stop breast cancer before it becomes invasive and malignant.…

Triple-negative breast cancer is aggressive, has a high rate of metastases, and carries a poor prognosis. Dr. Joyce O’Shaughnessy, who will be presenting at the Miami Breast Cancer Conference, discusses an overview of new therapies for triple-negative breast cancer.Cancer Network

We interview two prominent ovarian cancer researchers from both sides of the Atlantic, Dr. Michael Birrer and Dr. Jonathan Ledermann, on the role of PARP inhibitors and the challenges of developing ovarian cancer therapies.Cancer Network

In this interview, Christopher-Paul Milne and Kenneth Kaitin, Tufts Center for the Study of Drug Development. discuss the current challenges of the US Food and Drug Administration review process as it relates to oncology therapeutics and upcoming changes to the Prescription Drug User Fee Act.Cancer Network

Dr. Gunter von Minckwitz discusses the recent paper he authored that showed that bevacizumab in addition to neoadjuvant chemotherapy significantly increased the rate of pathological complete response in patients with early stage HER2-negative breast cancer.Cancer Network

In this interview, Dr. David Ahlquist, gastroenterologist and professor of medicine at the Mayo Clinic in Rochester in Minnesota, discusses early detection methods of colorectal cancer, touching on sigmoidoscopy, colonoscopies, fecal blood testing, and in particular, stool DNA screening.Cancer Network

We speak with Dr. Michael Atkins, who has extensive clinical experience in kidney cancer and development of various new treatments, and is presenting this weekend during the renal cancer translational science session at the American Society of Clinical Oncology 2012 Genitourinary Cancers Symposium.Cancer Network

Andrew Evens, DO, MSc, deputy director for clinical and translational research and medical director of the Clinical Research Office at the UMass Memorial Health Care Cancer Center of Excellence, talks about his research on lymphoma during pregnancy.Cancer Network

We interview Kent Osborne, the moderator of the year in review session. He has been involved with the meeting since its beginning. The international San Antonio Breast Cancer Symposium is unique as it facilitates the interaction of both basic and science researchers and clinicians to combine the efforts of laboratory research and clinical research …

We speak with Dr. Joseph Sparano, professor of medicine and women’s health at the Albert Einstein School of Medicine and associate chairman of the department of oncology at Montefiore Medical Center in New York, about the session he will chair at the ASCO Breast Cancer Symposium.Cancer Network

Dr. Susan O’Brien was one of the presenters at the ASCO 2011 session on therapies for chronic lymphocytic leukemia, in this podcast she gives some highlights of the session and insights into her own work.Cancer Network

We talk with Dr. David Mankoff, professor of radiology, medicine, and bioengineering in the department of radiology at the University of Washington in Seattle. Dr. Mankoff will be one of the co-chairs at the upcoming ASCO session on molecular imaging in cancer clinical trials, and he gives us a preview of what some of the highlights of the session …

The combination of biomarkers and molecular pathology will aid oncologists in developing targeted treatments for breast cancer, according to Samuel Aparicio, MD, PhD, who will be delivering a presentation on recognizing breast cancer heterogeneity in targeted treatment at the Miami Breast Cancer Conference this week.…

The early promise of treating triple-negative and basal-cell breast cancers with poly (ADP-ribose) polymerase (PARP) inhibitors is yet to be realized, according to Lisa A. Carey, MD, who will be delivering a presentation on treatment options for these patients at the Miami Breast Cancer Conference this week.…

The discovery of human epidermal growth factor receptor 2 (HER2)-positive breast cancer subtypes is not yet complete, according to Mark D. Pegram, MD, who will be delivering a presentation on the different clinical outcomes of these subtypes at the Miami Breast Cancer Conference this week.Cancer Network

Are genomic profiles refined enough that they should be used routinely to determine which breast cancer patients should receive adjuvant therapy? According to J. Michael Dixon, MD, who will be presenting the contra argument to this question in a debate at the Miami Breast Cancer Conference this week, the answer is: Not yet.…